A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

August 10, 2023

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

Solid TumorKRAS Mutation-Related Tumors

Interventions

DRUG

ZG2001 Tosilate Tablets

ZG2001 will be administered orally once or twice daily in a continuous regimen

Trial Locations (1)

RECRUITING

Chinese PLA General Hospital, Beijing

All Listed Sponsors

lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY